JP2010209076A5 - - Google Patents

Download PDF

Info

Publication number
JP2010209076A5
JP2010209076A5 JP2010081265A JP2010081265A JP2010209076A5 JP 2010209076 A5 JP2010209076 A5 JP 2010209076A5 JP 2010081265 A JP2010081265 A JP 2010081265A JP 2010081265 A JP2010081265 A JP 2010081265A JP 2010209076 A5 JP2010209076 A5 JP 2010209076A5
Authority
JP
Japan
Prior art keywords
gene
amount
expression level
patient
hya22
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010081265A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010209076A (ja
JP5285012B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010209076A publication Critical patent/JP2010209076A/ja
Publication of JP2010209076A5 publication Critical patent/JP2010209076A5/ja
Application granted granted Critical
Publication of JP5285012B2 publication Critical patent/JP5285012B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2010081265A 2003-12-31 2010-03-31 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法 Expired - Fee Related JP5285012B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53350503P 2003-12-31 2003-12-31
US60/533,505 2003-12-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006547537A Division JP4682152B2 (ja) 2003-12-31 2004-12-30 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012271426A Division JP5789591B2 (ja) 2003-12-31 2012-12-12 がん細胞の化学療法に対する抵抗性を克服するための阻害因子

Publications (3)

Publication Number Publication Date
JP2010209076A JP2010209076A (ja) 2010-09-24
JP2010209076A5 true JP2010209076A5 (https=) 2011-02-10
JP5285012B2 JP5285012B2 (ja) 2013-09-11

Family

ID=34748910

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006547537A Expired - Fee Related JP4682152B2 (ja) 2003-12-31 2004-12-30 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法
JP2010081265A Expired - Fee Related JP5285012B2 (ja) 2003-12-31 2010-03-31 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法
JP2012271426A Expired - Fee Related JP5789591B2 (ja) 2003-12-31 2012-12-12 がん細胞の化学療法に対する抵抗性を克服するための阻害因子

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006547537A Expired - Fee Related JP4682152B2 (ja) 2003-12-31 2004-12-30 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012271426A Expired - Fee Related JP5789591B2 (ja) 2003-12-31 2012-12-12 がん細胞の化学療法に対する抵抗性を克服するための阻害因子

Country Status (7)

Country Link
US (5) US7700280B2 (https=)
EP (2) EP1704250B1 (https=)
JP (3) JP4682152B2 (https=)
CN (3) CN102321584B (https=)
ES (1) ES2394799T3 (https=)
TW (1) TWI301066B (https=)
WO (1) WO2005066371A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102321584B (zh) * 2003-12-31 2014-01-08 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
EP3327031A1 (en) * 2004-05-14 2018-05-30 Abraxis BioScience, LLC Disease site-delivering pharmaceutical compositions comprising paclitaxel
AU2006249235B2 (en) * 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US7553496B2 (en) * 2004-12-21 2009-06-30 University Of Kentucky Research Foundation VEGF-A as an inhibitor of angiogenesis and methods of using same
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
CN101365806B (zh) * 2005-12-01 2016-11-16 医学预后研究所 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途
CA2651846C (en) * 2006-06-13 2019-11-12 The Rockefeller University Use of p11 to diagnose a p11/5-ht related disorder
DE102006035393A1 (de) * 2006-11-02 2008-05-15 Signature Diagnostics Ag Prognostische Marker für die Klassifizierung des dreijährigen progessionsfreien Überlebens von Patienten mit Kolonkarzinomen basierend auf Expressionsprofilen von biologischen Proben
US20110178154A1 (en) * 2007-02-06 2011-07-21 Birrer Michael J gene expression profile that predicts ovarian cancer subject response to chemotherapy
WO2008109519A2 (en) * 2007-03-02 2008-09-12 University Of South Florida Micro-rna profiles associated with endometrial cancer development and response to cisplatin and doxorubicin chemotherapy
US8034792B2 (en) 2007-09-11 2011-10-11 University Of Massachusetts Insulin-like growth factor binding protein 7 for treatment of cancer
JP5461201B2 (ja) * 2008-01-31 2014-04-02 学校法人慶應義塾 抗がん剤感受性の判定方法
US8093000B2 (en) * 2008-05-09 2012-01-10 The Regents Of The University Of California Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation
WO2010135786A1 (en) * 2009-05-29 2010-12-02 Clinical Genomics Pty. Ltd. A method for diagnosing neoplasms and molecules for use therein
CN102625839A (zh) * 2009-07-09 2012-08-01 阿布拉西斯生物科学有限责任公司 Sparc反义组合物和其用途
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
KR20120092597A (ko) * 2009-09-18 2012-08-21 아브락시스 바이오사이언스, 엘엘씨 암 치료에 있어 ｓｐａｒｃ 미세환경 시그니처의 용도
US8765713B2 (en) 2009-10-30 2014-07-01 Keio University Method for determination of sensitivity to anti-cancer agent
CA2800557A1 (en) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
DK2576638T3 (da) 2010-05-25 2021-03-15 Syndevrx Inc Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf
CA2801190A1 (en) 2010-06-03 2011-12-08 Abraxis Bioscience, Llc Use of the sparc microenvironment signature in the treatment of cancer
WO2012110425A1 (en) * 2011-02-14 2012-08-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for monitoring the response to treatment and for treating colorectal cancer
BR112013031019A2 (pt) * 2011-06-02 2017-03-21 Almac Diagnostics Ltd teste diagnóstico molecular para câncer
US9409978B2 (en) * 2011-09-09 2016-08-09 University Of Massachusetts Modulation of midbody derivatives
MX2015006955A (es) 2012-12-03 2016-01-25 Almac Diagnostics Ltd Prueba de diagnostico molecular para cancer.
CN105431426A (zh) 2013-04-10 2016-03-23 新德发制药有限公司 Metap2抑制剂和治疗肥胖症的方法
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
CN103893763B (zh) * 2014-04-10 2016-05-11 武汉大学 Vinexin-β基因在心肌梗死中的应用
CA2955914C (en) * 2014-07-21 2022-09-06 Ignacio Canals Almazan Tungsten (vi) salts for use thereof in the treatment of infertility, for favoring normal reproduction and fertility in a non-diabetic female mammal, as well as for improving the efficacy of assisted reproductive techniques
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
US9969722B2 (en) 2015-12-10 2018-05-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
CN108697807B (zh) * 2016-01-11 2021-11-26 辛德弗雷克斯公司 代谢功能障碍引起的肿瘤的治疗
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
EP3714896A4 (en) * 2017-11-21 2021-08-04 Miwa, Naofumi MEANS FOR INHIBITING METASTASISATION OF HUMAN CANCER CELLS AND MEANS FOR DETERMINING HUMAN CANCER CELLS
CN113196055B (zh) 2018-10-15 2025-06-27 马克斯·普朗克科学促进协会 用于治疗疾病的化合物及其筛选方法
CN113453721B (zh) 2018-10-26 2025-09-16 辛德弗雷克斯公司 Metap2抑制剂的生物标志物及其应用
CA3127237A1 (en) 2019-02-08 2020-08-13 Dewpoint Therapeutics, Inc. Methods of characterizing condensate-associated characteristics of compounds and uses thereof
CA3140651A1 (en) * 2019-05-15 2020-11-19 Whitehead Institute For Biomedical Research Methods of characterizing and utilizing agent-condensate interactions
CN110331203B (zh) * 2019-07-30 2023-04-18 中南大学湘雅三医院 泛素连接酶chaf1b作为靶位点在制备肺腺癌顺铂增敏药物中的应用
KR20220084047A (ko) 2019-09-18 2022-06-21 듀포인트 테라퓨틱스, 인크. 응축물 관련 특이성에 대한 스크리닝 방법 및 이의 용도
EP4329778A4 (en) * 2021-04-26 2025-02-19 Crititech, Inc. CISPLATIN PARTICLES AND THEIR USES
WO2023196540A1 (en) * 2022-04-06 2023-10-12 Vanderbilt University Articles and methods for inhibiting methionine aminopeptidase activity
WO2025057928A1 (ja) * 2023-09-11 2025-03-20 国立大学法人大阪大学 細胞外小胞内ｒｎａ修飾による卵巣癌プラチナ製剤抵抗性を判別するための検査方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5902880A (en) * 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US6146886A (en) * 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
CA2207593A1 (en) 1994-12-13 1996-06-20 John Gustofson Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
CA2301166A1 (en) 1997-07-24 1999-02-04 Yuan-Peng Zhang Liposomal compositions for the delivery of nucleic acid catalysts
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
JP2003528024A (ja) 1997-12-16 2003-09-24 バレンティス・インコーポレーテッド 製剤化された核酸分子の無針注入
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
EP1208191A4 (en) * 1999-08-13 2003-12-10 Human Genome Sciences Inc 13 HUMANE COLONAL AND COLONAL CANCER-ASSOCIATED PROTEINS
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
WO2001061048A2 (en) * 2000-02-17 2001-08-23 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification, assessment, prevention and therapy of human cancers
US7279294B2 (en) * 2000-04-03 2007-10-09 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih Tumor markers in ovarian cancer
US20020137663A1 (en) 2000-08-11 2002-09-26 Forman Barry M. The anti-neoplastic agent ET-743 inhibits trans activation by SXR
ATE365922T1 (de) * 2000-10-27 2007-07-15 Mount Sinai Hospital Corp Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
WO2002046765A2 (en) * 2000-11-08 2002-06-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US7195868B2 (en) * 2001-04-18 2007-03-27 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention, and therapy of human cancers
EP1451343B1 (en) * 2001-11-02 2012-10-17 Dana-Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof
AU2002357017A1 (en) * 2001-11-28 2003-06-10 Mediomics, Llc Anti-angiogenesis methods, compositions and uses therefor
WO2003078603A2 (en) * 2002-03-15 2003-09-25 Board Of Regents, The University Of Texas System Strong gene sets for glioma classification
US20040097452A1 (en) * 2002-11-19 2004-05-20 Isis Pharmaceuticals Inc. Modulation of kallikrein 6 expression
CN102321584B (zh) * 2003-12-31 2014-01-08 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
WO2006044017A2 (en) * 2004-08-13 2006-04-27 Jaguar Bioscience Inc. Systems and methods for identifying diagnostic indicators

Similar Documents

Publication Publication Date Title
JP2010209076A5 (https=)
JP7706728B2 (ja) 胆道がんの検出キット又はデバイス及び検出方法
JP7228896B2 (ja) 乳がん患者の予後の予測方法
JP6991433B2 (ja) 肺がんの検出キット又はデバイス及び検出方法
Pedersen et al. MicroRNA-based classifiers for diagnosis of oral cavity squamous cell carcinoma in tissue and plasma
JP2010516291A5 (https=)
JP6505656B2 (ja) 遺伝子の発現を分析することによって患者における癌の転帰を予測するための方法
JP2019516407A5 (https=)
JP2014516543A5 (https=)
JP2018505658A5 (https=)
JP2012503985A5 (https=)
JP2012510813A5 (https=)
Liu et al. Single nucleotide polymorphisms of microRNA processing machinery genes and outcome of hepatocellular carcinoma
WO2012093821A2 (ko) 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법
JP2010518811A5 (https=)
Izquierdo et al. Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma
CN113444804B (zh) 宫颈癌预后相关基因及其在制备宫颈癌预后预测诊断产品中的应用
JP6164689B2 (ja) 乳癌術前化学療法に対する感受性の診断補助方法および判定装置
JP2011528903A5 (https=)
TW201309805A (zh) 預測大腸直腸癌復發的生物標記
CN110023512A (zh) 用于预测乳腺癌患者的化疗有效性的方法
JP2014221834A5 (https=)
JP2018507692A (ja) マイクロｒｎａに基づく前立腺がん患者の予後評価方法
CN113736879A (zh) 用于小细胞肺癌患者预后的系统及其应用
CN104428426B (zh) 多发性硬化的诊断miRNA概况